FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Fate Therapeutics
Merck Sharp & Dohme LLC
AvenCell Therapeutics, Inc.
Incyte Corporation
Gilead Sciences
Allogene Therapeutics
Genmab
Genmab
Genmab
Ossium Health, Inc.
Ossium Health, Inc.
AstraZeneca
AvenCell Therapeutics, Inc.
ARCE Therapeutics, Inc.
Sana Biotechnology
Actinium Pharmaceuticals
Sanofi
TriArm Therapeutics (Taiwan) Limited
Gilead Sciences
CERo Therapeutics Holdings, Inc.
Caribou Biosciences, Inc.
Amgen
Indapta Therapeutics, INC.
Janssen Research & Development, LLC
AvenCell Therapeutics, Inc.
Nkarta, Inc.
Hoffmann-La Roche
Celgene
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Bellicum Pharmaceuticals
Fate Therapeutics
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Bristol-Myers Squibb
TCR2 Therapeutics
Shanghai Ming Ju Biotechnology Co., Ltd.
Precision BioSciences, Inc.
Kiadis Pharma
Nohla Therapeutics, Inc.
TC Biopharm
Hebei Senlang Biotechnology Inc., Ltd.
Celularity Incorporated
Celyad Oncology SA
Hoffmann-La Roche
Beijing Immunochina Medical Science & Technology Co., Ltd.
Hoffmann-La Roche
Nohla Therapeutics, Inc.